Luca Castagna, Massimo Magagnoli, Monica Demarco, Armando Santoro

Research output: Contribution to journalArticlepeer-review


Many progresses have been made in the management of non-Hodgkin's lymphoma and Hodgkin's lymphoma. Newer chemotherapeutic regimens, extended use of PET to evaluate the stage and mainly the response after treatment, rituximab and other monoclonal antibodies, radioimmunoconjugates, and allogeneic stem cell transplantation, all contribute to a better treatment of these diseases. Furthermore, risk-adapted treatment can reduce late toxicities, such as cardiovascular disease, secondary myelodysplastic syndrome, and solid tumors.

Original languageEnglish
Pages (from-to)101-110
Number of pages10
JournalUpdate on Cancer Therapeutics
Issue number2
Publication statusPublished - Jun 2007


  • Chemotherapy
  • Hodgkin's lymphoma
  • Non-Hodgkin's lymphoma
  • PET

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Lymphomas'. Together they form a unique fingerprint.

Cite this